Evidence map›Paper›PMID 18446217›Full record

ArticlePloS one2008

Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans.

Stephen M Todryk, Philip Bejon, Tabitha Mwangi, Magdalena Plebanski, Britta Urban, Kevin Marsh, Adrian V S Hill, Katie L Flanagan

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02925403 (A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers), which is not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02925403 phase1 / phase2completednot on this mapstarted 2016, after this paper: background citation

A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers

TypeinterventionalSponsorUniversity of OxfordRan2016 to 2017Enrolled13ConditionsMalariaArmsR21/Matrix-M1, Saline
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Vaccines · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Frontiers in cellular and infection microbiology · 2020
    Article
  18. Article
  19. T cell-mediated immunity to malaria.Nature reviews. Immunology · 2019
    Review
  20. Interferon-PeerJ · 2017
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Stephen M TodrykCentre for Clinical Vaccinology and Tropical Medicine, Oxford University, Churchill Hospital, Oxford, United Kingdom. stephen.todryk@unn.ac.uk
Philip Bejon
Tabitha Mwangi
Magdalena Plebanski
Britta Urban
Kevin Marsh
Adrian V S Hill
Katie L Flanagan
Churchill Hospital · GBKenya Medical Research Institute · KEUniversity of Oxford · GBMonash University · AUMRC Unit the Gambia · GM

Funding

Medical Research CouncilWellcome Trust 079082
6 · The paper itself

Abstract

backgroundImmunity to malaria develops naturally in endemic regions, but the protective immune mechanisms are poorly understood. Many vaccination strategies aim to induce T cells against diverse pre-erythrocytic antigens, but correlates of protection in the field have been limited. The objective of this study was to investigate cell-mediated immune correlates of protection in natural malaria. Memory T cells reactive against thrombospondin-related adhesive protein (TRAP) and circumsporozoite (CS) protein, major vaccine candidate antigens, were measured, as were frequencies of CD4(+) CD25(high) T cells, which may suppress immunity, and CD56(+) NK cells and gammadelta T cells, which may be effectors or may modulate immunity. METHODOLOGY AND PRINCIPAL

findings112 healthy volunteers living in rural Kenya were entered in the study. Memory T cells reactive against TRAP and CS were measured using a cultured IFNgamma ELISPOT approach, whilst CD4(+) CD25(high) T cells, CD56(+) NK cells, and gammadelta T cells were measured by flow cytometry. We found that T cell responses against TRAP were established early in life (<5 years) in contrast to CS, and cultured ELISPOT memory T cell responses did not correlate with ex-vivo IFNgamma ELISPOT effector responses. Data was examined for associations with risk of clinical malaria for a period of 300 days. Multivariate logistic analysis incorporating age and CS response showed that cultured memory T cell responses against TRAP were associated with a significantly reduced incidence of malaria (p = 0.028). This was not seen for CS responses. Higher numbers of CD4(+) CD25(high) T cells, potentially regulatory T cells, were associated with a significantly increased risk of clinical malaria (p = 0.039).

conclusionsThese data demonstrate a role for central memory T cells in natural malarial immunity and support current vaccination strategies aimed at inducing durable protective T cell responses against the TRAP antigen. They also suggest that CD4(+) CD25(high) T cells may negatively affect naturally acquired malarial immunity.

Indexed as

AdolescentAdultAgedAged, 80 and overBlack PeopleCD4 AntigensCells, CulturedChildChild, PreschoolCytokinesDisease SusceptibilityHumansImmunologic MemoryIncidenceInfantInfant, NewbornCD4 AntigensCytokinesInterferon-gammaInterleukin-2 Receptor alpha SubunitProtozoan Proteinsthrombospondin-related adhesive protein, protozoan

Identifiers

PMID18446217
PMCPMC2323567
OpenAlexW2012973954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.